Alcohol's Impact on Inflammatory Markers in HIV Disease - Russia ARCH Cohort
Alcohol & Zinc Impact on Inflammatory Markers in HIV Disease - Russia ARCH Cohort
2 other identifiers
observational
351
1 country
1
Brief Summary
The purpose of this study is to assess the longitudinal association between alcohol consumption and biomarkers of microbial translocation (sCD14) and inflammation/altered coagulation (IL-6/D-dimer); to establish a cohort of HIV-infected Russian drinkers; and to establish a sample repository.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 25, 2012
CompletedFirst Posted
Study publicly available on registry
June 8, 2012
CompletedStudy Start
First participant enrolled
November 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 15, 2020
CompletedDecember 17, 2020
December 1, 2020
5.4 years
May 25, 2012
December 16, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Microbial translocation as measured by soluble CD14 (sCD14)
Participants will be followed for up to 3 years
Secondary Outcomes (2)
Inflammation/altered coagulation as measured by IL-6/D-dimer
Participants will be followed for up to 3 years
Alcohol's association with immunologic aging as measured by flow cytometry
Participants will be followed for up to 3 years
Eligibility Criteria
This is a study of HIV-infected adults who are ART naive at enrollment. Subjects will be recruited from a recently completed NIAAA trial (HERMITAGE; NCT00483483) and from HIV and addiction care sites.
You may qualify if:
- Age 18-70 years old
- HIV-infected
- Provision of contact information for two contacts to assist with follow-up
- Stable address within St. Petersburg or districts within 100 kilometers of St. Petersburg
- Possession of a home or mobile phone
- ART-naive at the time of enrollment
You may not qualify if:
- Not fluent in Russian
- Cognitive impairment resulting in inability to provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Pavlov State Medical University
Saint Petersburg, Russia
Related Links
Biospecimen
We are storing serum and plasma for future use, as well as dried blood spots for PEth testing.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jeffrey Samet, MD, MA, MPH
Boston Medical Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief, Section of General Internal Medicine
Study Record Dates
First Submitted
May 25, 2012
First Posted
June 8, 2012
Study Start
November 1, 2012
Primary Completion
April 1, 2018
Study Completion
December 15, 2020
Last Updated
December 17, 2020
Record last verified: 2020-12
Data Sharing
- IPD Sharing
- Will not share